

Abstract

Provided are a compound having a new structure as a 5-HT_{2A} receptor agonist, a preparation method therefor, and the use thereof in the treatment of diseases related to the 5-HT_{2A} receptor. Experiments have confirmed that the compounds have a strong affinity on the 5-HT_{2A} receptor, and can be used as a promising compound for treating diseases related to the 5-HT_{2A} receptor.

[No suitable figure]